Logo image of LXU

LSB INDUSTRIES INC (LXU) Stock Fundamental Analysis

NYSE:LXU - New York Stock Exchange, Inc. - US5021601043 - Common Stock - Currency: USD

7.32  -0.02 (-0.27%)

After market: 7.32 0 (0%)

Fundamental Rating

3

Taking everything into account, LXU scores 3 out of 10 in our fundamental rating. LXU was compared to 85 industry peers in the Chemicals industry. LXU scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. LXU is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

LXU had positive earnings in the past year.
In the past year LXU had a positive cash flow from operations.
In multiple years LXU reported negative net income over the last 5 years.
Of the past 5 years LXU 4 years had a positive operating cash flow.
LXU Yearly Net Income VS EBIT VS OCF VS FCFLXU Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M

1.2 Ratios

LXU has a worse Return On Assets (-2.26%) than 68.24% of its industry peers.
LXU's Return On Equity of -5.43% is on the low side compared to the rest of the industry. LXU is outperformed by 62.35% of its industry peers.
Industry RankSector Rank
ROA -2.26%
ROE -5.43%
ROIC N/A
ROA(3y)5.51%
ROA(5y)-2.47%
ROE(3y)15.37%
ROE(5y)-5.05%
ROIC(3y)N/A
ROIC(5y)N/A
LXU Yearly ROA, ROE, ROICLXU Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40

1.3 Margins

In the last couple of years the Operating Margin of LXU has declined.
LXU has a worse Gross Margin (7.56%) than 85.88% of its industry peers.
In the last couple of years the Gross Margin of LXU has grown nicely.
The Profit Margin and Operating Margin are not available for LXU so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 7.56%
OM growth 3Y-59.74%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-28.46%
GM growth 5Y46.21%
LXU Yearly Profit, Operating, Gross MarginsLXU Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20

More info and screens

4

2. Health

2.1 Basic Checks

LXU does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, LXU has less shares outstanding
The number of shares outstanding for LXU has been increased compared to 5 years ago.
Compared to 1 year ago, LXU has an improved debt to assets ratio.
LXU Yearly Shares OutstandingLXU Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
LXU Yearly Total Debt VS Total AssetsLXU Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

2.2 Solvency

Based on the Altman-Z score of 1.33, we must say that LXU is in the distress zone and has some risk of bankruptcy.
LXU's Altman-Z score of 1.33 is on the low side compared to the rest of the industry. LXU is outperformed by 68.24% of its industry peers.
LXU has a Debt/Equity ratio of 0.99. This is a neutral value indicating LXU is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.99, LXU is doing worse than 67.06% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.99
Debt/FCF N/A
Altman-Z 1.33
ROIC/WACCN/A
WACC8.93%
LXU Yearly LT Debt VS Equity VS FCFLXU Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M 600M

2.3 Liquidity

LXU has a Current Ratio of 2.51. This indicates that LXU is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.51, LXU is in the better half of the industry, outperforming 74.12% of the companies in the same industry.
LXU has a Quick Ratio of 2.29. This indicates that LXU is financially healthy and has no problem in meeting its short term obligations.
LXU has a better Quick ratio (2.29) than 84.71% of its industry peers.
Industry RankSector Rank
Current Ratio 2.51
Quick Ratio 2.29
LXU Yearly Current Assets VS Current LiabilitesLXU Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 56.67% over the past year.
Looking at the last year, LXU shows a decrease in Revenue. The Revenue has decreased by -4.23% in the last year.
LXU shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 7.43% yearly.
EPS 1Y (TTM)56.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-69.23%
Revenue 1Y (TTM)-4.23%
Revenue growth 3Y-2.07%
Revenue growth 5Y7.43%
Sales Q2Q%3.78%

3.2 Future

The Earnings Per Share is expected to decrease by -8.48% on average over the next years.
LXU is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.23% yearly.
EPS Next Y-56.71%
EPS Next 2Y-17.94%
EPS Next 3Y-8.48%
EPS Next 5YN/A
Revenue Next Year11.98%
Revenue Next 2Y5.58%
Revenue Next 3Y5.98%
Revenue Next 5Y3.23%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
LXU Yearly Revenue VS EstimatesLXU Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M
LXU Yearly EPS VS EstimatesLXU Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 2 -2

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 15.57 indicates a correct valuation of LXU.
Based on the Price/Earnings ratio, LXU is valued a bit cheaper than the industry average as 62.35% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of LXU to the average of the S&P500 Index (25.82), we can say LXU is valued slightly cheaper.
Based on the Price/Forward Earnings ratio of 19.41, the valuation of LXU can be described as rather expensive.
Compared to the rest of the industry, the Price/Forward Earnings ratio of LXU is on the same level as its industry peers.
LXU's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 21.76.
Industry RankSector Rank
PE 15.57
Fwd PE 19.41
LXU Price Earnings VS Forward Price EarningsLXU Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

LXU's Enterprise Value to EBITDA is on the same level as the industry average.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 9.32
LXU Per share dataLXU EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

LXU's earnings are expected to decrease with -8.48% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-17.94%
EPS Next 3Y-8.48%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LXU!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LSB INDUSTRIES INC

NYSE:LXU (5/23/2025, 8:32:48 PM)

After market: 7.32 0 (0%)

7.32

-0.02 (-0.27%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)04-29 2025-04-29/amc
Earnings (Next)07-29 2025-07-29/amc
Inst Owners53.58%
Inst Owner Change2.5%
Ins Owners4.27%
Ins Owner Change0.23%
Market Cap526.16M
Analysts77.78
Price Target8.75 (19.54%)
Short Float %3.75%
Short Ratio4
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)102.45%
Min EPS beat(2)69.76%
Max EPS beat(2)135.15%
EPS beat(4)4
Avg EPS beat(4)103.34%
Min EPS beat(4)69.76%
Max EPS beat(4)135.15%
EPS beat(8)6
Avg EPS beat(8)43.21%
EPS beat(12)8
Avg EPS beat(12)22.5%
EPS beat(16)10
Avg EPS beat(16)37.33%
Revenue beat(2)2
Avg Revenue beat(2)9.9%
Min Revenue beat(2)6.25%
Max Revenue beat(2)13.55%
Revenue beat(4)3
Avg Revenue beat(4)6.5%
Min Revenue beat(4)-6.62%
Max Revenue beat(4)13.55%
Revenue beat(8)7
Avg Revenue beat(8)5.28%
Revenue beat(12)10
Avg Revenue beat(12)4.96%
Revenue beat(16)11
Avg Revenue beat(16)3.09%
PT rev (1m)-8.72%
PT rev (3m)-17.5%
EPS NQ rev (1m)-11.54%
EPS NQ rev (3m)-31.09%
EPS NY rev (1m)-25%
EPS NY rev (3m)-51.68%
Revenue NQ rev (1m)-2.06%
Revenue NQ rev (3m)-4.97%
Revenue NY rev (1m)1.68%
Revenue NY rev (3m)5.25%
Valuation
Industry RankSector Rank
PE 15.57
Fwd PE 19.41
P/S 1
P/FCF N/A
P/OCF 7.59
P/B 1.07
P/tB 1.08
EV/EBITDA 9.32
EPS(TTM)0.47
EY6.42%
EPS(NY)0.38
Fwd EY5.15%
FCF(TTM)-0.36
FCFYN/A
OCF(TTM)0.96
OCFY13.17%
SpS7.34
BVpS6.82
TBVpS6.81
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.26%
ROE -5.43%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 7.56%
FCFM N/A
ROA(3y)5.51%
ROA(5y)-2.47%
ROE(3y)15.37%
ROE(5y)-5.05%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)9.64%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-59.74%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-28.46%
GM growth 5Y46.21%
F-Score4
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 0.99
Debt/FCF N/A
Debt/EBITDA 6.46
Cap/Depr 122.77%
Cap/Sales 17.98%
Interest Coverage N/A
Cash Conversion 92.06%
Profit Quality N/A
Current Ratio 2.51
Quick Ratio 2.29
Altman-Z 1.33
F-Score4
WACC8.93%
ROIC/WACCN/A
Cap/Depr(3y)96.58%
Cap/Depr(5y)76.59%
Cap/Sales(3y)11.38%
Cap/Sales(5y)9.83%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)56.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-69.23%
EPS Next Y-56.71%
EPS Next 2Y-17.94%
EPS Next 3Y-8.48%
EPS Next 5YN/A
Revenue 1Y (TTM)-4.23%
Revenue growth 3Y-2.07%
Revenue growth 5Y7.43%
Sales Q2Q%3.78%
Revenue Next Year11.98%
Revenue Next 2Y5.58%
Revenue Next 3Y5.98%
Revenue Next 5Y3.23%
EBIT growth 1Y-106.18%
EBIT growth 3Y-60.57%
EBIT growth 5YN/A
EBIT Next Year2157.36%
EBIT Next 3Y195.04%
EBIT Next 5Y92.67%
FCF growth 1Y-109.71%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-78.3%
OCF growth 3Y-0.4%
OCF growth 5Y110.4%